Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Cabozantinib and atezolizumab show more efficacy compared to second NHT in patients with mCRPC

Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA
Cabozantinib and atezolizumab show more efficacy compared to second NHT in patients with mCRPC ( Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA )
30 Jan 2024

Baseline characteristics of patients with PSMA-PET–positive and –negative disease with high-risk BCR after radical RP

Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany
Baseline characteristics of patients with PSMA-PET–positive and –negative disease with high-risk BCR after radical RP ( Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany )
30 Jan 2024

Enfortumab vedotin in combination with pembrolizumab is a potential new standard of care for 1L la/mUC

Dr Michiel Simon Van Der Heijden - Netherlands Cancer Institute, Amsterdam, Netherlands
Enfortumab vedotin in combination with pembrolizumab is a potential new standard of care for 1L la/mUC ( Dr Michiel Simon Van Der Heijden - Netherlands Cancer Institute, Amsterdam, Netherlands )
30 Jan 2024

Lenvatinib and pembrolizumab show promising efficacy in first-line treatment of aRCC

Prof Viktor Grünwald - University Hospital Essen, Essen, Germany
Lenvatinib and pembrolizumab show promising efficacy in first-line treatment of aRCC ( Prof Viktor Grünwald - University Hospital Essen, Essen, Germany )
30 Jan 2024

Enzalutamide monotherapy prolongs MFS compared to leuprolide alone in men with high-risk biochemically recurrent PC

Dr Neal Shore - Carolina Urologic Research Center, Myrtle Beach, USA
Enzalutamide monotherapy prolongs MFS compared to leuprolide alone in men with high-risk biochemically recurrent PC ( Dr Neal Shore - Carolina Urologic Research Center, Myrtle Beach, USA )
30 Jan 2024

Combination of cabozantinib and atezolizumab shows moderate activity in treating metastatic adrenocortical carcinoma

Dr Enrique Grande - MD Anderson Cancer Center Madrid, Madrid, Spain
Combination of cabozantinib and atezolizumab shows moderate activity in treating metastatic adrenocortical carcinoma ( Dr Enrique Grande - MD Anderson Cancer Center Madrid, Madrid, Spain )
30 Jan 2024

Durvalumab plus bevacizumab, added to TACE, shows benefit for unresectable hepatocellular carcinoma

Dr Riccardo Lencioni - University of Pisa, Pisa, Italy
Durvalumab plus bevacizumab, added to TACE, shows benefit for unresectable hepatocellular carcinoma ( Dr Riccardo Lencioni - University of Pisa, Pisa, Italy )
25 Jan 2024

What is new for treatment of soft tissue and bone sarcomas?

Dr Silvia Stacchiotti - The National Cancer Institute of Milan, Italy
What is new for treatment of soft tissue and bone sarcomas? ( Dr Silvia Stacchiotti - The National Cancer Institute of Milan, Italy )
25 Jan 2024

Cancer personomics: Launching the missile - Localised endometrial carcinoma.

Dr Patricia Pautier - Institute Gustave Roussy, Villejuif, France
Cancer personomics: Launching the missile - Localised endometrial carcinoma. ( Dr Patricia Pautier - Institute Gustave Roussy, Villejuif, France )
25 Jan 2024

Novel therapies and combinations in ovarian cancer

Dr Alexandria Leary - Institute Gustave Roussy, Villejuif, France
Novel therapies and combinations in ovarian cancer ( Dr Alexandria Leary - Institute Gustave Roussy, Villejuif, France )
25 Jan 2024

What's new on ADCs in management of advanced NSCLC

Dr David Planchard - Institute Gustave Roussy, Villejuif, France
What's new on ADCs in management of advanced NSCLC ( Dr David Planchard - Institute Gustave Roussy, Villejuif, France )
25 Jan 2024

Treatment of metastatic NSCLC without PD-L1 expression and without oncogene addiction

Dr Antonio Passaro - European Institute of Oncology, Milan, Italy
Treatment of metastatic NSCLC without PD-L1 expression and without oncogene addiction ( Dr Antonio Passaro - European Institute of Oncology, Milan, Italy )
25 Jan 2024